Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

DLK inhibitor shows promising data in vivo

May 4, 2018

No Comments

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

May 4, 2018

No Comments

Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC

May 4, 2018

No Comments

Phase I data on CD34+ therapy presented for retinal degeneration

May 3, 2018

No Comments

Microrod formulation of travoprost provides sustained release

May 3, 2018

No Comments

Kodiak Sciences describes KSI-301, an anti-VEGF therapy with extended half-life

May 2, 2018

No Comments

Rhopressa launched in the U.S. for lowering intraocular pressure

May 2, 2018

No Comments

4DMT and Roche expand ophthalmology partnership

May 2, 2018

No Comments

ThromboGenics initiates phase II trial of THR-317 with Lucentis for DME

April 27, 2018

No Comments

First patient enrolled in phase III trial of topical ocular reproxalap

April 25, 2018

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

DLK inhibitor shows promising data in vivo

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC

Phase I data on CD34+ therapy presented for retinal degeneration

Microrod formulation of travoprost provides sustained release

Kodiak Sciences describes KSI-301, an anti-VEGF therapy with extended half-life

Rhopressa launched in the U.S. for lowering intraocular pressure

4DMT and Roche expand ophthalmology partnership

ThromboGenics initiates phase II trial of THR-317 with Lucentis for DME

First patient enrolled in phase III trial of topical ocular reproxalap

Today's news in brief

Today's news in brief

Second insulin receptor offers new therapeutic avenues

Mechanism underlying so-called idiopathic autism inception unveiled

Drug duo to Repare lack in gyno cancers? Phase I shows promise

Ocular RSS

Ocular
RSS